dalteparin has been researched along with Coronary Thrombosis in 44 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| "Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging." | 2.74 | Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. ( Antman, EM; Cheng, S; Morrow, DA; Sabatine, MS; Sloan, S, 2009) |
| " However, close scrutiny of the methodology of the clinical trials in UCAD reveals considerable differences in study designs, dosage regimens, duration of administration of active treatments, and the timing and definition of endpoints." | 2.41 | Can we differentiate the low-molecular-weight heparins? ( Turpie, AG, 2000) |
| " In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization." | 1.39 | Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013) |
| " Rivaroxaban was also effective following oral dosing at 3 mg/kg." | 1.37 | Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. ( Andrade-Gordon, P; Chen, C; Connelly, MA; Damiano, BP; Huang, Z; Parry, TJ; Perzborn, E, 2011) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Aspirin pretreatment increased the tongue-bleeding time, whereas the addition of CRL42796 or enoxaparin did not prolong bleeding time to a further degree." | 1.32 | Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven ( Driscoll, EM; Giboulot, TA; Hong, TT; Lucchesi, BR; Sherigill, A; White, AJ, 2003) |
| " These data suggest that enoxaparin is more effective and potentially safer than heparin when combined with a GPIIb/IIIa receptor antagonist during rt-PA-induced coronary thrombolysis." | 1.31 | Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. ( Bentley, RG; Bostwick, JS; Chu, V; Kasiewski, CJ; Klein, SI; Leadley, RJ; Morgan, SR; Perrone, MH; Rebello, SS, 2001) |
| "Occlusive coronary thrombosis was induced in 5 groups of 10 dogs by placing a copper coil into the left anterior descending coronary artery." | 1.29 | Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. ( Arnout, J; Collen, D; Dol, F; Herbert, JM; Jun, L; Lormeau, JC; Van de Werf, F; Vanhove, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (15.91) | 18.2507 |
| 2000's | 24 (54.55) | 29.6817 |
| 2010's | 13 (29.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jun, L | 1 |
| Arnout, J | 1 |
| Vanhove, P | 1 |
| Dol, F | 1 |
| Lormeau, JC | 1 |
| Herbert, JM | 1 |
| Collen, D | 1 |
| Van de Werf, F | 1 |
| Idir, M | 1 |
| Madonna, F | 1 |
| Roudaut, R | 1 |
| Turpie, AG | 1 |
| Lin, AN | 1 |
| Lin, S | 1 |
| Lin, K | 1 |
| Gokhroo, R | 1 |
| De la Torre Hernández, JM | 1 |
| Sadaba Sagredo, M | 1 |
| Telleria Arrieta, M | 1 |
| Gimeno de Carlos, F | 1 |
| Sanchez Lacuesta, E | 1 |
| Bullones Ramírez, JA | 1 |
| Pineda Rocamora, J | 1 |
| Martin Yuste, V | 1 |
| Garcia Camarero, T | 1 |
| Larman, M | 1 |
| Rumoroso, JR | 1 |
| Romero-Castro, MJ | 1 |
| Seoane-García, T | 1 |
| Chaparro-Muñoz, M | 1 |
| García-Borbolla, R | 1 |
| García-Rubira, JC | 1 |
| Echavarría-Pinto, M | 1 |
| Lopes, R | 1 |
| Gorgadze, T | 1 |
| Gonzalo, N | 1 |
| Hernández, R | 1 |
| Jiménez-Quevedo, P | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Nuñez-Gil, IJ | 1 |
| Ibañez, B | 1 |
| Fernández, C | 1 |
| Fernandez-Ortiz, A | 1 |
| García, E | 1 |
| Macaya, C | 2 |
| Escaned, J | 1 |
| Mele, M | 1 |
| Martimucci, M | 1 |
| Maggi, A | 1 |
| Villella, A | 1 |
| Villella, M | 1 |
| Langialonga, T | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Cheng, S | 1 |
| Morrow, DA | 1 |
| Sloan, S | 1 |
| Antman, EM | 1 |
| Sabatine, MS | 1 |
| Rao, SV | 1 |
| Ohman, EM | 1 |
| Sorajja, D | 1 |
| Bhakta, MD | 1 |
| Altemose, GT | 1 |
| Wong, CK | 1 |
| White, HD | 2 |
| Martí, V | 1 |
| García-Picart, J | 1 |
| Carballeira, L | 1 |
| Parry, TJ | 1 |
| Huang, Z | 1 |
| Chen, C | 1 |
| Connelly, MA | 1 |
| Perzborn, E | 1 |
| Andrade-Gordon, P | 1 |
| Damiano, BP | 1 |
| Silvain, J | 1 |
| Montalescot, G | 2 |
| Gerbaud, E | 1 |
| Seguy, B | 1 |
| Coste, P | 1 |
| Brosa, M | 1 |
| Rubio-Terrés, C | 1 |
| Farr, I | 1 |
| Nadipelli, V | 1 |
| Froufe, J | 1 |
| Power, GE | 1 |
| Rogers, P | 1 |
| Fitchett, D | 1 |
| Goodman, SG | 1 |
| Gupta, M | 1 |
| Langer, A | 1 |
| Uzan, A | 1 |
| Monroe, VS | 1 |
| Kerensky, RA | 1 |
| Rivera, E | 1 |
| Smith, KM | 1 |
| Pepine, CJ | 1 |
| Hong, TT | 1 |
| Driscoll, EM | 1 |
| White, AJ | 1 |
| Sherigill, A | 1 |
| Giboulot, TA | 1 |
| Lucchesi, BR | 1 |
| Lawrence, M | 1 |
| Mixon, TA | 1 |
| Cross, D | 1 |
| Gantt, DS | 1 |
| Dehmer, GJ | 1 |
| Boztosun, B | 1 |
| Gunes, Y | 1 |
| Kirma, C | 1 |
| Barutcu, I | 1 |
| Bontadelli, J | 1 |
| Moeller, A | 1 |
| Schmugge, M | 1 |
| Schraner, T | 1 |
| Kretschmar, O | 1 |
| Bauersfeld, U | 1 |
| Bernet-Buettiker, V | 1 |
| Albisetti, M | 1 |
| Friedewald, VE | 1 |
| Bates, ER | 1 |
| Granger, CB | 1 |
| Yusuf, S | 1 |
| Roberts, WC | 1 |
| Nasser, NJ | 1 |
| Abadi, S | 1 |
| Azzam, ZS | 1 |
| Kirsch, M | 1 |
| Vermes, E | 1 |
| Boval, B | 1 |
| Drouet, L | 1 |
| Loisance, D | 1 |
| Cohen, M | 1 |
| Salette, G | 1 |
| Desmet, WJ | 1 |
| Aylward, PE | 1 |
| Steg, PG | 1 |
| Gallo, R | 1 |
| Steinhubl, SR | 1 |
| Leadley, RJ | 3 |
| Kasiewski, CJ | 3 |
| Bostwick, JS | 3 |
| Bentley, R | 2 |
| McVey, MJ | 1 |
| White, FJ | 1 |
| Perrone, MH | 3 |
| Dunwiddie, CT | 2 |
| Zidar, JP | 3 |
| Stone, GW | 1 |
| Harvey, DM | 1 |
| Offord, RH | 1 |
| Rebello, SS | 1 |
| Bentley, RG | 1 |
| Morgan, SR | 1 |
| Chu, V | 1 |
| Klein, SI | 1 |
| Salvioni, A | 1 |
| Casilli, F | 1 |
| Assanelli, E | 1 |
| Grazi, M | 1 |
| Marenzi, G | 1 |
| Guazzi, MD | 1 |
| Batchelor, WB | 1 |
| Mahaffey, KW | 2 |
| Berger, PB | 2 |
| Deutsch, E | 1 |
| Meier, S | 1 |
| Hasselblad, V | 1 |
| Fry, ET | 2 |
| Teirstein, PS | 1 |
| Ross, AM | 1 |
| Binanay, CA | 1 |
| Massel, D | 1 |
| Cruickshank, MK | 1 |
| Meier, SJ | 1 |
| Buller, CE | 1 |
| Batchelor, W | 1 |
| Baumbach, A | 1 |
| Oberhoff, M | 1 |
| Rübsamen, K | 1 |
| Jochims, K | 1 |
| Herdeg, C | 1 |
| Kranzhöfer, A | 1 |
| Safer, A | 1 |
| Karsch, KR | 1 |
| Abdelmoneim, SS | 1 |
| Pellikka, PA | 1 |
| Mulvagh, SL | 1 |
| Johanson, P | 1 |
| Wallentin, L | 1 |
| Nilsson, T | 1 |
| Bergstrand, L | 1 |
| Lindahl, B | 1 |
| Dellborg, M | 1 |
| Bijsterveld, NR | 1 |
| Moons, AH | 1 |
| Meijers, JC | 1 |
| Tijssen, JG | 1 |
| Büller, HR | 1 |
| Levi, M | 1 |
| Peters, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844] | Phase 2/Phase 3 | 3,532 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for dalteparin and Coronary Thrombosis
| Article | Year |
|---|---|
Can we differentiate the low-molecular-weight heparins?
Topics: Anticoagulants; Clinical Trials as Topic; Coronary Thrombosis; Dalteparin; Drug Administration Sched | 2000 |
Anticoagulant therapy for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as Topic; Coronary Th | 2010 |
Antithrombotic therapy in ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Electrocardiography; Enoxaparin | 2011 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
[Thrombosis and ischemia: experimental data].
Topics: Animals; Apoptosis; Coronary Thrombosis; Disease Models, Animal; Dogs; Enoxaparin; Fibrinolytic Agen | 2002 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Art | 2003 |
Management of venous and cardiovascular thrombosis: enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Myoc | 2000 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
7 trials available for dalteparin and Coronary Thrombosis
| Article | Year |
|---|---|
Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Coronary Artery Disease; Coronary Thromb | 2009 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Fem | 1998 |
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Biomarkers; Cardiovascular | 2001 |
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B | 2001 |
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (
Topics: Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Ag | 2002 |
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Dalteparin; Female; Fibrinolysis; Heparin; He | 2002 |
29 other studies available for dalteparin and Coronary Thrombosis
| Article | Year |
|---|---|
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Heparin; Myocardial Reperfusion; Nadroparin; Thrombolyt | 1995 |
Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical heart valve prosthesis during low-molecular weight heparin therapy.
Topics: Aged; Anticoagulants; Coronary Thrombosis; Female; Heart Valve Prosthesis; Humans; Mitral Valve; Nad | 1999 |
A giant left atrial thrombus.
Topics: Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Echocardiography, Transesophageal; Enoxapa | 2017 |
Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Coronary Thrombosis; Drug Administ | 2017 |
A 70-Year-Old Woman With a Prosthetic Mitral Valve and Sudden Chest Pain.
Topics: Aged; Angina Pectoris; Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Graft Occlusion | 2018 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi | 2013 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog | 2015 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Left atrial Lasso catheter thrombus aspiration.
Topics: Atrial Fibrillation; Catheter Ablation; Coronary Thrombosis; Enoxaparin; Female; Heart Atria; Humans | 2010 |
[Acute coronary syndrome due to distal embolization of a thrombus located in the left main coronary artery].
Topics: Acute Coronary Syndrome; Angina Pectoris; Angiography; Anticoagulants; Coronary Thrombosis; Electroc | 2011 |
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carotid Artery Injuries; Coronary | 2011 |
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxap | 2012 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angi | 2012 |
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Coronary Dise | 2002 |
Retroperitoneal haematoma associated with low molecular weight heparin.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Combined Modality Therapy; Coronary Thrombosis; Drug The | 2002 |
Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven
Topics: Animals; Aspirin; Blood Coagulation; Coronary Thrombosis; Dipeptides; Disease Models, Animal; Dogs; | 2003 |
Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation; Coronary Thrombosis; Enoxaparin; | 2004 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinatio | 2006 |
Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease.
Topics: Anticoagulants; Cardiac Catheterization; Cohort Studies; Coronary Thrombosis; Enoxaparin; Female; He | 2007 |
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes.
Topics: Administration, Cutaneous; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Comorbidity; C | 2007 |
Acute renal infarction from a cardiac thrombus.
Topics: Abdominal Pain; Acute Disease; Anticoagulants; Cardiomyopathy, Dilated; Coronary Thrombosis; Diagnos | 2007 |
[Four years of circulatory support with the INCOR axial pump from Berlin Heart].
Topics: Clopidogrel; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Heart Failure; Heart-Assist Devic | 2007 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev | 1997 |
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Topics: Animals; Anticoagulants; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-R | 1998 |
Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
Topics: Abciximab; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.
Topics: Animals; Blood Flow Velocity; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combi | 2001 |
Porous balloon delivery of low molecular weight heparin in the dog coronary artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Catheterization; Coronary Thrombosis; Coronary Vessels; Dog | 1996 |
Contrast echocardiography for assessment of left ventricular thrombi.
Topics: Aged; Anticoagulants; Contrast Media; Coronary Thrombosis; Dalteparin; Diagnosis, Differential; Fema | 2014 |
ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy.
Topics: Aged; Coronary Angiography; Coronary Thrombosis; Dalteparin; Electrocardiography; Female; Fibrinolyt | 2004 |